Skip Navigation


JAC Advance Access originally published online on April 21, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/6/1045    most recent
dkh224v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Toledo, M. J. O.
Right arrow Articles by Lana, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toledo, M. J. O.
Right arrow Articles by Lana, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 1045-1053
© 2004 The British Society for Antimicrobial Chemotherapy

Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes

M. J. O. Toledo1,2,*, M. T. Bahia3, V. M. Veloso3, C. M. Carneiro4, G. L. L. Machado-Coelho5, C. F. Alves3, H. R. Martins4, R. E. Cruz4, W. L. Tafuri2,3 and M. Lana4

1 Departamento de Análises Clínicas, Centro de Ciências da Saúde, Bloco I-90, Universidade Estadual de Maringá, Av. Colombo, 5790, 87020-900, Maringá, PR; 2 Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Campus Pampulha, 31270-901, Belo Horizonte, MG; 3 Departamento de Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Campus Universitário Morro do Cruzeiro, Universidade Federal de Ouro Preto (UFOP), 35400-000, Ouro Preto, MG; 4 Departamento de Análises Clínicas and 5 Departamento de Farmácia, Escola de Farmácia, Rua Costa Sena, 171, UFOP, 35400-000, Ouro Preto, MG, Brazil

Received 13 December 2002; returned 7 March 2003; revised 11 December 2003; accepted 3 March 2004

The goal of this study was to verify the effect of specific treatment on parasitological and histopathological parameters in mice experimentally infected with different Trypanosoma cruzi clonal genotypes. Twenty cloned stocks were selected, representative of the whole phylogenetic diversity of the protozoan and belonging to the clonal genotypes 19 and 20 (T. cruzi I) and 39 and 32 (T. cruzi II). The stocks were inoculated in 40 BALB/c mice divided into four groups: (i) treated with benznidazole, (ii) treated with itraconazole and (iii and iv) untreated control groups (NT) for each drug, respectively. Seven parameters related to parasitaemia curves and histopathological lesions were analysed. Four during the acute phase (AP) and three during both the AP and chronic phase (CP) of infection. Statistical comparison between benznidazole-treated and NT groups for the biological parameters showed significant differences for all genotypes. Benznidazole treatment led to lower patent period, maximum of parasitaemia, day of maximum parasitaemia and area under the parasitaemia curve for all genotypes analysed. Percentage of positive haemoculture during AP and CP was lower for genotypes 19 and 32. Tissue parasitism (TP) and inflammatory process (IP) during AP were lower for genotypes 19 and 32, respectively. In general, itraconazole treatment induced a smaller reduction in these same parameters between treated and NT animals in relation to benznidazole treatment. Our results indicate that phylogenetic divergence among T. cruzi clonal genotypes must be taken in account in chemotherapy and studies dealing with all aspects of the parasite and the disease.

Keywords: experimental chemotherapy, benznidazole, itraconazole, genetic groups

* Corresponding author. Tel: +55-44-2614518; Fax: +55-44-2614490; E-mail: mjotoledo{at}uem.br


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
H. R. Martins, L. M. Figueiredo, J. C. O. Valamiel-Silva, C. M. Carneiro, G. L. L. Machado-Coelho, D. M. Vitelli-Avelar, M. T. Bahia, O. A. Martins-Filho, A. M. Macedo, and M. Lana
Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes
J. Antimicrob. Chemother., June 1, 2008; 61(6): 1319 - 1327.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
D. A. Rendon
Mitochondrial Bioenergetics after Nine-Day Treatment Regimen with Benzonidazole in Rats
International Journal of Toxicology, November 1, 2007; 26(6): 571 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. R. Martins, R. M. Silva, H. M. S. Valadares, M. J. O. Toledo, V. M. Veloso, D. M. Vitelli-Avelar, C. M. Carneiro, G. L. L. Machado-Coelho, M. T. Bahia, O. A. Martins-Filho, et al.
Impact of Dual Infections on Chemotherapeutic Efficacy in BALB/c Mice Infected with Major Genotypes of Trypanosoma cruzi
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3282 - 3289.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Garcia, C. O. Ramos, J. F. V. Senra, F. Vilas-Boas, M. M. Rodrigues, A. C. Campos-de-Carvalho, R. Ribeiro-dos-Santos, and M. B. P. Soares
Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations
Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1521 - 1528.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.